Merck and Abide to develop diabetes drugs in deal potentially worth $430M

05/3/2013 | Genetic Engineering & Biotechnology News

Merck & Co. and Abide Therapeutics will collaborate in the discovery, development and marketing of small molecule drugs for type 2 diabetes and other metabolic conditions. The target will be serine hydrolases, a family of enzymes. The deal entitles Abide to as much as $430 million in an upfront payment, research funding and milestone fees for three products, plus sales royalties. Merck will get the global rights to market any drugs arising from the collaboration.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA